Across TCGA pan-cancer cohorts, CXCL5 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CXCL5 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher CXCL5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CXCL5 expression acts as an unfavorable survival marker.
ESCA are the cancer types where CXCL5 Mutation most reproducibly stratifies survival.